Vasomune Therapeutics and AnGes expand the scope of the co-development agreement to target additional indications

Vasomune Therapeutics Inc., and AnGes Inc., recently announced that they have entered into an agreement to expand the research indications for the Tie2 receptor agonist Pegevongitide (AV-001) currently under joint development. To date, Vasomune and AnGes have been conducting clinical trials of Pegevongitide (AV-001), targeting Acute Respiratory Distress Syndrome arising from viral and bacterial pneumonia.

Vasomune Therapeutics is an alumnus of our BDSP™ and CAAP® programs, and presented at the OBIO® Investment Summit.